US-based startup medical device company, Seigla Medical, have received CE mark for its guide catheter extnesion used during coronary and peripheral vasculature interventions.
According to Seigla, guide catheter extensions are used annually in over 500,000 interventional procedures worldwide. The market for these devices is growing based on an aging population and factors that are increasing anatomic complexity.
Seigla co-founder, president and CEO Chad Kugler said in a statement:
The LiquID device is built on a proprietary and unique technical platform that miniaturises device components, strengthens performance and provides significantly larger internal diameters.
These attributes help interventionalists perform a wider array of challenging procedures in today’s world of complex intervention.
This technology is Seigla’s first product launch and is a precursor for the company to apply this platform to additional devices and additional clinical specialties
Contego Medical CEO and founder Ravish Sachar shared:
CE Marking of the Neuroguard IEP System is an important milestone for Contego Medical and allows us to bring the remarkable safety and performance benefits of the Neuroguard stent to patients in Europe.
We anticipate launching the product in select countries, as well as initiating a post-marketing clinical study in the coming months.
Furthermore, Seigla announced the completion of the first PCI cases using the LiquID device. In a press release, Dr. Julian Strange (Bristol Heart Institute, UK) after performing three separate coronary procedures said:
The LiquID’s exemplary support and flexibility were equally matched by the reassuring feeling of deliverability and ease of use,
The design remit of unparalleled performance in complex coronary work has been fully realized in this world-leading guide catheter extension.
Source: Medical Device Network